Cytochrome P450 epoxygenases as EDHF synthase(s)

Pharmacological Research

Volumn 49, Issue 6, 2004, Pages 525-533

  Fleming, Ingrid ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Angiogenesis; Calcium dependent potassium channels; Epoxyeicosatrienoic acids; Gap junctions; Soluble epoxide hydrolase

Indexed keywords

APAMIN; ARACHIDONIC ACID; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM ION; CHARYBDOTOXIN; CYTOCHROME P450; DEXAMETHASONE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; FLUINDOSTATIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBERIOTOXIN; NIFEDIPINE; PHENOBARBITAL; POTASSIUM CHANNEL; POTASSIUM ION; RETINOIC ACID; SULFAPHENAZOLE; XENOBIOTIC AGENT;

BLOOD VESSEL TONE; CALCIUM TRANSPORT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; ENZYME SUBSTRATE; HOMEOSTASIS; HYPERPOLARIZATION; LIQUID; METABOLISM; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SHEAR STRESS; SIGNAL PROCESSING;

EID: 1542722060     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.11.016     Document Type: Article

References (110)

1. McGuire J.J., Ding H., Triggle C.R. Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s). Can. J. Physiol. Pharmacol. 79:2001;443-470.
2. Randall M.D., Alexander S.P.H., Bennett T., Boyd E.A., Fry J.R., Gardiner S.M.et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:1996;114-120.
3. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I.et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 401:1999;493-497.
4. Matoba T., Shimokawa H., Kubota H., Morikawa K., Fujiki T., Kunihiro I. et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem. Biophys. Res. Commun. 209:2002;909-913.
5. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 396:1998;269-272.
6. Busse R., Edwards G., Feletou M., Fleming I., Vanhoutte P.M., Weston A.H. EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23:2002;374-380.
7. Pinto A., Abraham N.G., Mullane K.M. Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450 dependent pathway. J. Pharmacol. Exp. Ther. 240:1987;856-882.
8. Rubanyi G.M., Vanhoutte P.M. Nature of endothelium-derived relaxing factor: are there two relaxing mediators? Circ. Res. 61:1987;SII-61-SII-67.
9. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267:1992;11789-11793.
10. Popp R., Bauersachs J., Hecker M., Fleming I., Busse R. A transferable, β-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J. Physiol. (Lond.). 497:1996;699-709.
11. Fisslthaler B., Hinsch N., Chataigneau T., Popp R., Kiss L., Busse R.et al. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension. 36:2000;270-275.
12. Wang M.H., Brand-Schieber E., Zand B.A., Nguyen X., Falck J.R., Balu N. et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther. 284:1998;966-973.
13. Gauthier K.M., Deeter C., Krishna U.M., Reddy Y.K., Bondlela M., Falck J.R.et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ. Res. 90:2002;1028-1036.
14. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)- enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension 2003;42:555-561.
15. Hecker M., Bara A.T., Bauersachs J., Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J. Physiol. (Lond.). 481:1994;407-414.
16. Bauersachs J., Hecker M., Busse R. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br. J. Pharmacol. 113:1994;1548-1553.
17. Fulton D., Mahboubi K., McGiff J.C., Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br. J. Pharmacol. 114:1995;99-102.
18. Campbell W.B., Gebremedhin D., Pratt P.F., Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78:1996;415-423.
19. Arima S., Endo Y., Yaoita H., Omata K., Ogawa S., Tsunoda K.et al. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J. Clin. Invest. 100:1997;2816-2823.
20. Weintraub N.L., Fang X., Kaduce T.L., VanRollins M., Chatterjee P., Spector A.A. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ. Res. 81:1997;258-267.
21. Fulton D., McGiff J.C., Quilley J. Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J. Pharmacol. Exp. Ther. 287:1998;497-503.
22. + channels. Circulation. 99:1999;3132-3138.
23. Nishikawa Y., Stepp D.W., Chilian W.M. In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation. Am. J. Physiol. 277:1999;H1252-H1259.
24. 2 contribute to ACh-induced hyperpolarization of pressurized canine coronary microvessels. Am. J. Physiol. Heart Circ. Physiol. 285:2003;H1939-H1948.
25. Ca channels. Circulation. 107:2003;769-776.
26. Halcox J.P., Narayanan S., Cramer-Joyce L., Mincemoyer R., Quyyumi A.A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol. Heart Circ. Physiol. 208:2001;H2470-H2477.
27. Coats P., Johnston F., MacDonald J., McMurray J.J.V., Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation. 103:2001;1702-1708.
28. Hillig T., Krustrup P., Fleming I., Osada T., Saltin B., Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J. Physiol. (Lond.). 546:2003;307-314.
29. Büssemaker E., Popp R., Binder J., Busse R., Fleming I. Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery. Kidney Int. 63:2003;1749-1755.
30. Capdevila J., Chacos N., Werringloer J., Prough R.A., Estabrook R.W. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc. Natl. Acad. Sci. U.S.A. 78:1981;5362-5366.
31. +)ATPase. Nature. 314:1985;620-622.
32. Coon M.J., Ding X.X., Pernecky S.J., Vaz A.D. Cytochrome P450: progress and predictions. FASEB J. 6:1992;669-673.
33. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. New York: Plenum Press; 1995. p. 473-535.
34. Nguyen X., Wang M.H., Reddy K.M., Falck J.R., Schwartzman M.L. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am. J. Physiol. 276:1999;R1691-R1700.
35. Oyekan A.O., McGiff J.C. Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am. J. Physiol. 274:1998;R52-R61.
36. Imig J.D., Pham B.T., LeBlanc E.A., Reddy K.M., Falck J.R., Inscho E.W. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension. 35:2000;307-312.
37. Hercule H.C., Oyekan A.O. Cytochrome P450 w/w-1 hydroxylase-derived eicosanoids contribute to endothelinA and endothelinB receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J. Pharmacol. Exp. Ther. 292:2000;1153-1160.
38. Escalante B.A., McGiff J.C., Oyekan A.O. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am. J. Physiol. Renal Physiol. 282:2002;F144-F150.
39. Chu Z.M., Croft K.D., Kingsbury D.A., Falck J.R., Reddy K.M., Beilin L.J. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo. Clin. Sci. (Colch.). 98:2000;277-282.
40. Kauser K., Clark J.E., Masters B.S., Ortiz de Montellano P.R., Ma Y.H., Harder D.R.et al. Inhibitors of cytochrome P-450 attenuate the myogenic response of dog renal arcuate arteries. Circ. Res. 68:1991;1154-1163.
41. Ma Y.H., Gebremedhin D., Schwartzman M.L., Falck J.R., Clark J.E., Masters B.S.et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ. Res. 72:1993;126-136.
42. Zou A.P., Imig J.D., Kaldunski M., Ortiz de Montellano P.R., Sui Z., Roman R.J. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am. J. Physiol. 266:1994;F275-F282.
43. Imig J.D., Zou A.P., Stec D.E., Harder D.R., Falck J.R., Roman R.J. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am. J. Physiol. 270:1996;R217-R227.
44. Harder D.R., Lange A.R., Gebremedhin D., Birks E.K., Roman R.J. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J. Vasc. Res. 34:1997;237-243.
45. Gebremedhin D., Lange A.R., Lowry T.F., Taheri M.R., Birks E.K., Hudetz A.G.et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ. Res. 87:2000;60-65.
46. Zeldin D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276:2001;36059-36062.
47. Fisslthaler B., Popp R., Michaelis U.R., Kiss L., Fleming I., Busse R. Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension. 38:2001;1427-1432.
48. Earley S., Walker B.R. Endothelium-dependent blunting of myogenic responsiveness after chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 283:2002;H2202-H2209.
49. Earley S., Pastuszyn A., Walker B.R. Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 285:2003;H127-H136.
50. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M.et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29:2001;242-251.
51. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277:2002;209-217.
52. de Morais S.M.F., Schweikl H., Blaisdell J., Goldstein J.A. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 194:1993;194-201.
53. Ged C., Beaune P. Isolation of the human cytochrome P-450 IIC8 gene: multiple glucocorticoid responsive elements in the 5′ region. Biochim. Biophys. Acta. 1088:1991;433-435.
54. Bauersachs J., Christ M., Ertl G., Michaelis U.R., Fisslthaler B., Busse R.et al. Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc. Res. 54:2002;669-675.
55. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:1996;209-215.
56. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.P.et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27:1999;410-416.
57. Qiu W.P., Hu Q., Paolocci N., Zeigelstein R.C., Kass D.A. Differential effects of pulsatile versus steady flow on coronary endothelial membrane potential. Am. J. Physiol. Heart Circ. Physiol. 285:2003;H341-H346.
58. Oesch-Bartlomowicz B., Richter B., Becker R., Vogel S., Padma P.R., Hengstler J.G.et al. cAMP-dependent phosphorylation of CYP2B1 as a functional switch for cyclophosphamide activation and its hormonal control in vitro and in vivo. Int. J. Cancer. 94:2001;733-742.
59. Korsmeyer K.K., Davoll S., Figueiredo-Pereira M.E., Correia M.A. Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome? Arch. Biochem. Biophys. 365:1999;31-44.
60. Anandatheerthavarada H.K., Biswas G., Mullick J., Sepuri N.B., Otvos L., Pain D.et al. Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP-dependent phosphorylation at Ser128. EMBO J. 18:1999;5494-5504.
61. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W.et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87:2000;992-998.
62. Fang X., Kaduce T.L., Weintraub N.L., Harmon S., Teesch L.M., Morisseau C.et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276:2001;14867-14874.
63. Capdevila J.H., Kishore V., Dishman E., Blair I.A., Falck J.R. A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem. Biophys. Res. Commun. 146:1987;638-644.
64. VanRollins M., Kaduce T.L., Fang X., Knapp H.R., Spector A.A. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J. Biol. Chem. 271:1996;14001-14009.
65. Karara A., Dishman E., Falck J.R., Capdevila J.H. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J. Biol. Chem. 266:1991;7561-7569.
66. Shivachar A.C., Willoughby K.A., Ellis E.F. Effect of protein kinase C modulators on 14,15-epoxyeicosatrienoic acid incorporation into astroglial phospholipids. J. Neurochem. 65:1995;338-346.
67. Zygmunt P.M., Högestätt E.D. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br. J. Pharmacol. 117:1996;1600-1606.
68. Gauthier K.M., Liu C., Popovic A., Albarwani S., Rusch N.J. Freshly isolated bovine coronary endothelial cells do not express the BK Ca channel gene. J. Physiol. 545:2002;829-836.
69. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ. Res. 80:1997;877-884.
70. + channel on pig coronary artery endothelial cells. J. Physiol. (Lond.). 504.3:1997;537-543.
71. Imig J.D., Inscho E.W., Deichamnn P.C., Reddy K.M., Falck J.R. Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension. 33:1999;408-413.
72. + channel modulated by a functionally associated protein kinase. Nature. 369:1994;563-565.
73. Desaphy J.F., Joffre M. Effect of cyclic AMP on the calcium-dependent potassium conductances of rat Leydig cells. Can. J. Physiol. Pharmacol. 76:1998;649-656.
74. Watanabe H., Vriens J., Prenen J., Droogmans G., Voets T., Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels 434. Nature. 424:2003;434-438.
75. Karara A., Wei S., Spady D., Swift L., Capdevila J.H., Falck J.R. Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem. Biophys. Res. Commun. 182:1992;1320-1325.
76. Popp R., Brandes R.P., Ott G., Busse R., Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ. Res. 90:2002;800-806.
77. Hoepfl B., Rodenwaldt B., Pohl U., de Wit C. EDHF, but not NO or prostaglandins, is critical to evoke a conducted dilation upon ACh in hamster arterioles. Am. J. Physiol. Heart Circ. Physiol. 283:2002;H996-H1004.
78. Zhang Y., Oltman C.L., Lu T., Lee H.C., Dellsperger K.C., VanRollins M. EET homologues potently dilate coronary microvessels and activate BKCa channels. Am. J. Physiol. Heart Circ. Physiol. 280:2001;H2430-H2440.
79. Büssemaker E., Popp R., Fisslthaler B., Larson C.M., Fleming I., Busse R.et al. Aged spontaneously hypertensive rats exhibit a selective loss of EDHF-mediated relaxation in the renal artery. Hypertension. 42:2003;562-568.
80. Yu Z., Huse L.M., Adler P., Graham L., Ma J., Zeldin D.C.et al. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol. Pharmacol. 57:2000;1011-1020.
81. Frisbee J.C., Falck J.R., Lombard J.H. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am. J. Physiol. Heart Circ. Physiol. 278:2000;H1517-H1526.
82. Kroetz D.L., Huse L.M., Thuresson A., Grillo M.P. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol. Pharmacol. 52:1997;362-372.
83. Omata K., Abraham N.G., Escalante B., Schwartzman M.L. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am. J. Physiol. 262:1992;F8-F16.
84. Pomposiello S.I., Carroll M.A., Falck J.R., McGiff J.C. Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension. 37:2001;887-893.
85. Holla V.R., Makita K., Zaphiropoulos P.G., Capdevila J.H. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J. Clin. Invest. 104:1999;751-760.
86. Pfister S.L., Falck J.R., Campbell W.B. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am. J. Physiol. 261:1991;H843-H852.
87. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 94:1996;3341-3347.
88. McCulloch A.I., Bottrill F.E., Randall M.D., Hiley C.R. Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br. J. Pharmacol. 120:1997;1431-1438.
89. Kessler P., Popp R., Busse R., Schini-Kerth V.B. Proinflammatory mediators chronically down-regulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation. 99:1999;1878-1884.
90. Kim Y.M., Bergonia H.A., Muller C., Pitt B.R., Watkins W.D., Lancaster J.R. Jr. Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J. Biol. Chem. 270:1995;5710-5713.
91. Stadler J., Trockfeld J., Schmalix W.A., Brill T., Seiwert J.R., Greim H.et al. Inhibition of cytochromes P4501A by nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3559-3563.
92. Mehl M., Daiber A., Herold S., Shoun H., Ullrich V. Peroxynitrite reaction with heme proteins. Nitric Oxide. 3:1999;142-152.
93. Minamiyama Y., Takemura S., Inoue M. Effect of thiol status on nitric oxide metabolism in the circulation. Arch. Biochem. Biophys. 341:1997;186-192.
94. Lopez-Garcia M.P., Sanz-Gonzalez S.M. Peroxynitrite generated from constitutive nitric oxide synthase mediates the early biochemical injury in short-term cultured hepatocytes. FEBS Lett. 466:2000;187-191.
95. Vernia S., Sanz-Gonzalez S.M., Lopez-Garcia M.P. Involvement of peroxynitrite on the early loss of p450 in short-term hepatocyte cultures. Adv. Exp. Med. Biol. 500:2001;209-212.
96. Vernia S., Beaune P., Coloma J., Lopez-Garcia M.P. Differential sensitivity of rat hepatocyte CYP isoforms to self-generated nitric oxide. FEBS Lett. 488:2001;59-63.
97. Davydov D.R. Microsomal monooxygenase in apoptosis: another target for cytochrome c signaling? Trends Biochem. Sci. 26:2001;155-160.
98. Fleming I., Michaelis U.R., Bredenkötter D., Fisslthaler B., Dehghani F., Brandes R.P.et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. 88:2001;44-51.
99. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004;109:178-183.
100. Puntarulo S., Cederbaum A.I. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic. Biol. Med. 24:1998;1324-1330.
101. Wu D., Cederbaum A.I. Removal of glutathione produces apoptosis and necrosis in HepG2 cells overexpressing CYP2E1. Alcohol Clin. Exp. Res. 25:2001;619-628.
102. Nieto N., Friedman S.L., Greenwel P., Cederbaum A. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology. 30:2001;987-996.
103. Yang B., Graham L., Dikalov S., Mason R.P., Falck J.R., Liao J.K.et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol. 60:2001;310-320.
104. Fleming I. Cytochrome P450 and vascular homeostasis. Circ. Res. 89:2001;753-762.
105. Munzenmaier D.H., Harder D.R. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am. J. Physiol. Heart Circ. Physiol. 278:2000;H1163-H1167.
106. Medhora M., Daniels J., Mundey K., Mundey K. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 284:2003;H215-H224.
107. Michaelis U.R., Fisslthaler B., Medhora M.et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17:2003;770-772.
108. Chen J.K., Wang D.-W., Falck J.R.et al. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15- epoxyeicosatrienoic acid functions as an intracellular messenger in response to epidermal growth factor. J. Biol. Chem. 274:1999;4764-4769.
109. Potente M., Michaelis U.R., Fisslthaler B.et al. CYP 2C9-induced endothelial cell proliferation involves induction of MAP kinase phosphatase 1, inhibition of the c-Jun N-terminal kinase and upregulation of cyclin D1. J. Biol. Chem. 277:2002;15671-15676.
110. Kip1. J. Biol. Chem. 278:2003;29619-29625.